Beiersdorf stock weighs Derma growth against NIVEA weakness

Beiersdorf is balancing strong growth in its Derma brands against continued weakness at NIVEA after a mixed third quarter. In its release published on October 27, the Hamburg-based consumer goods group said organic sales declined 1.3 percent to 2.362 billion euros, while management maintained its full-year 2026 forecast.

Beiersdorf stock traded at 84.58 euros on Lang & Schwarz at 10:03 CET on Friday, November 13, 0.93 percent above the Xetra close of Thursday, November 12, at 83.80 euros. The quotation puts the share close to the level investors have monitored since the company reported its third-quarter figures.

Derma remains the growth engine

The Derma business, led by Eucerin and Aquaphor, delivered organic sales growth of 10.6 percent in the third quarter. Beiersdorf said the advance was broad-based across regions and categories, supported by product innovation and expansion into new market segments. In North America, the expansion of Aquaphor into body care made a strong start.

La Prairie also accelerated, with organic sales growth of 8.5 percent. China remained the main growth driver, while the launch of the Swiss Pristine entry line broadened the luxury brand's reach. The Health Care business, including Hansaplast and Elastoplast, grew 5.7 percent organically.

NIVEA turnaround still faces pressure

NIVEA organic sales fell 4.9 percent in the quarter. Beiersdorf attributed the decline to temporary sell-in headwinds, including trade-related tensions and retailer destocking, although sales dynamics improved from the second quarter. The company expects these factors to fade gradually by the end of the year.

Chief Executive Vincent Warnery said the NIVEA turnaround plan was progressing and pointed to positive early traction from launches such as FACE+ in Europe. The plan emphasizes innovation across categories, a stronger value-for-money proposition and greater use of local consumer insights. Global NIVEA sell-out continued to grow, which management described as an early sign that rebalancing measures are gaining traction.

Guidance leaves execution in focus

Beiersdorf confirmed its expectation of a low-single-digit organic sales decline for the Consumer Business Segment in 2026 and an adjusted EBIT margin of at least 11.0 percent. At group level, the company expects the same broad sales trend and an EBIT margin excluding special factors of at least 11.8 percent.

The tesa business remains a separate risk factor. Organic sales declined 4.3 percent in the third quarter as semiconductor shortages weighed on the Electronics business. Beiersdorf still expects tesa sales to remain flat to slightly higher organically for the full year, but warned that the shortage could further pressure performance and the margin through an unfavorable product mix.

For investors, the central question is whether improving NIVEA sell-out can translate into healthier retailer inventories and stronger sell-in during the fourth quarter. Derma and La Prairie provide portfolio support, but the difficult comparison base and ongoing NIVEA measures leave the near-term earnings profile dependent on execution.

Investors tracking German equities can find broader market coverage in the DAX market section.

Further company-specific developments are available in More news and analyses on Beiersdorf stock.

Beiersdorf's third-quarter 2026 results release provides the company's detailed figures and outlook.